Search | TVST | ARVO Journals

Showing 1 – 20 of 27

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Efficacy and safety of a low dose dexamethasone implant for diabetic macular edema and retinal vein occlusion: Results of the First-In-Human Phase 2 RIPPLE-1 trial

Hemal Mehta; Kelli Wootton; Madeline Simpson; Gillian Mackey; Wendy Naimark

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6253.

ARVO Annual Meeting Abstract June 2024

Linking multimodal image-linkage with the FRB! registry to enhance its globally impactful research potential – the beginning of “FRB! 2.0”.

Ash Kras; Mark C Gillies; Jennifer Arnold; Daniel Barthelmes; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5631.

ARVO Annual Meeting Abstract June 2024

A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)

loic Cm lhuillier; Hemal Mehta; Jagjit Gilhotra; Fred Chen; Sanjeewa Wickremasinghe; Wilson Heriot; Peter Davies; Lily Ooi; Jennifer Arnold; Rohan Merani; Mike Taylor; David O Bates; Samantha Fraser-Bell; Mark C Gillies; Mario G Fsadni; Andrew Chang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6248.

ARVO Annual Meeting Abstract June 2023

Six-month Outcomes of Brolucizumab in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry

Mark Gillies; trung dang; Vuong Nguyen; Alessandro Invernizzi; Francesco Romano; Mariano Cozzi; Jennifer Arnold; james wong; hemal mehta; samantha Fraser-Bell; Richard Barry; Daniel Barthelmes; Alan Luckie

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):466.

ARVO Annual Meeting Abstract June 2022

36-month outcomes of VEGF inhibitors for treatment-naïve Central Retinal Vein Occlusion: Data from the Fight Retinal Blindness! registry.

Adrian Hunt; Vuong Nguyen; Sanjeeb Bhandari; Jennifer J Arnold; Ian McAllister; Hemal Mehta; Alessandro Invernizzi; David Squirrell; Theodorus Ponsioen; Pierre-Henry GABRIELLE; Louise O’ Toole; Javier Zarranz-Ventura; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2674.

ARVO Annual Meeting Abstract June 2020

Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.

SANJEEB BHANDARI; Vuong Nguyen; Samantha Fraser-Bell; Hemal Mehta; Francesco Viola; Florian Baudin; Pierre-Henry Gabrielle; Catherine P Creuzot Garcher; Mark C Gillies; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3289.

Articles May 2020

A Mitochondrial Genome-Wide Association Study of Cataract in a Latino Population

PDF

Brendan Miller; Mina Torres; Xuejuan Jiang; Roberta McKean-Cowdin; Darryl Nousome; Su-Jeong Kim; Hemal H. Mehta; Kelvin Yen; Pinchas Cohen; Rohit Varma
TAGS: cataract, genome-wide association study, hispanics or latinos, mitochondria
Trans. Vis. Sci. Tech.. 2020; 9(6):25. https://doi.org/10.1167/tvst.9.6.25

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2019

Visual outcomes and optical coherence tomography features in young adults born extremely preterm: The EPICure@19 Study

Siva Balasubramanian; Saurabh Jain; Joanne Beckmann; Karntida Chanwimol; Marco Nassisi; Irena Tsui; Neil Marlow; Srinivas R Sadda; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4754.

ARVO Annual Meeting Abstract July 2019

A randomised clinical trial of slow versus fast intravitreal injection of ranibizumab (Lucentis®) and its impact on intraocular pressure (the Speed IOP Study)

Samantha Fraser-Bell; Sophia Zagora; Hemal Mehta; Anna Campain; Hon Seng Wong; Yeung Aaron; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):79.

ARVO Annual Meeting Abstract July 2019

Changes in real world treatment patterns for diabetic macular edema and five year treatment outcomes: data from the Fight Retinal Blindness! Project

SANJEEB BHANDARI; Anne Catherine Biechl; Jennifer Joan Arnold; Stephanie Young; Samanta Fraser-Bell; Hemal Mehta; Mark C Gillies; Daniel Barthelmes; Vuong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2602.

ARVO Annual Meeting Abstract July 2019

Real-world outcomes in patients with macular oedema secondary to central retinal vein occlusion receiving intravitreal anti-VEGF therapy in a UK public hospital setting

Sarah Ah-Moye; Pardis Zalmay; Magnus Theodorsson; Martin Lynn Harris; Riaz Asaria; Adrian Hunt; Daniel Barthelmes; Mark C Gillies; Vuong Nguyen; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4061.

ARVO Annual Meeting Abstract July 2018

Five year outcomes of the Bevordex Study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone).

Elisa Eleanor Cornish; Kelvin Yi Chong Teo; Mark C Gillies; Lyndell L Lim; Ian McAllister; Sutha Sanmugasundram; Vuong Nguyen; Sanjeewa Wickremasinghe; Hemal Mehta; Samantha Fraser-Bell

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4847.

ARVO Annual Meeting Abstract July 2018

Real-world visual outcomes at 24 weeks in patients with diabetic macular edema receiving aflibercept intravitreal injections as per UK license.

Charles Hennings; Mira Deshmukh; Vuong Nguyen; Martin Harris; Riaz Asaria; Daniel Barthelmes; Mark C Gillies; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3616.

ARVO Annual Meeting Abstract June 2017

The mitochondrial-derived peptide humanin improves mitochondrial bioenergetics after endoplasmic reticulum stress in human RPE cells

Hiroto Terasaki; Parameswaran G Sreekumar; Hemal H Mehta; Pinchas Cohen; David R Hinton; Ram Kannan

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5361.

ARVO Annual Meeting Abstract June 2017

Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years – Results from the BEVORDEX randomized clinical trial of bevacizumab versus dexamethasone implants for diabetic macular edema

Hemal Mehta; Samantha Fraser-Bell; Vuong Nguyen; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1895.

ARVO Annual Meeting Abstract June 2017

Clinical, optical coherence tomography and fundus autofluorescence findings in atrophic maculopathy associated with pseudoxanthoma elasticum

Panagiotis Vasilopoulos; Andrew R Webster; Catherine A Egan; Hemal Mehta; Philip G Hykin

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4639.

ARVO Annual Meeting Abstract June 2017

Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept (Eylea) intravitreal injections at fixed intervals as per UK license

Mehmet Ozturk; Martin Harris; Vuong Nguyen; Daniel Barthelmes; Mark C Gillies; Hemal Mehta

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):881.

ARVO Annual Meeting Abstract September 2016

Humanin enhances mitochondrial biogenesis in RPE cells

Parameswaran G Sreekumar; Hiroto Terasaki; Christine Spee; Hemal H Mehta; Junxiang Wan; Kelvin Yen; Pinchas Cohen; Ram Kannan; David R Hinton

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5016.

ARVO Annual Meeting Abstract September 2016

Progression of Diabetic Retinopathy in the Bevordex study: a randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema

Lyndell L Lim; Dania Qatarneh; Lauren Hodgson; Hemal Mehta; Sanjeewa Wickremasinghe; Anna Campain; Mark C Gillies; Samantha Fraser-Bell

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2106.

ARVO Annual Meeting Abstract September 2016

Subretinal fluid in Macular telangiectasia type 2 without apparent choroidal neovascularization

Hemal Mehta; Simona Degli Esposti; Catherine A Egan; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4443.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Efficacy and safety of a low dose dexamethasone implant for diabetic macular edema and retinal vein occlusion: Results of the First-In-Human Phase 2 RIPPLE-1 trial

Linking multimodal image-linkage with the FRB! registry to enhance its globally impactful research potential – the beginning of “FRB! 2.0”.

A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)

Six-month Outcomes of Brolucizumab in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry

36-month outcomes of VEGF inhibitors for treatment-naïve Central Retinal Vein Occlusion: Data from the Fight Retinal Blindness! registry.

Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.

A Mitochondrial Genome-Wide Association Study of Cataract in a Latino Population

Visual outcomes and optical coherence tomography features in young adults born extremely preterm: The EPICure@19 Study

A randomised clinical trial of slow versus fast intravitreal injection of ranibizumab (Lucentis®) and its impact on intraocular pressure (the Speed IOP Study)

Changes in real world treatment patterns for diabetic macular edema and five year treatment outcomes: data from the Fight Retinal Blindness! Project

Real-world outcomes in patients with macular oedema secondary to central retinal vein occlusion receiving intravitreal anti-VEGF therapy in a UK public hospital setting

Five year outcomes of the Bevordex Study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone).

Real-world visual outcomes at 24 weeks in patients with diabetic macular edema receiving aflibercept intravitreal injections as per UK license.

The mitochondrial-derived peptide humanin improves mitochondrial bioenergetics after endoplasmic reticulum stress in human RPE cells

Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years – Results from the BEVORDEX randomized clinical trial of bevacizumab versus dexamethasone implants for diabetic macular edema

Clinical, optical coherence tomography and fundus autofluorescence findings in atrophic maculopathy associated with pseudoxanthoma elasticum

Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept (Eylea) intravitreal injections at fixed intervals as per UK license

Humanin enhances mitochondrial biogenesis in RPE cells

Progression of Diabetic Retinopathy in the Bevordex study: a randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema

Subretinal fluid in Macular telangiectasia type 2 without apparent choroidal neovascularization

To View More...

You must be signed into an individual account to use this feature.